Siemens unveils AI and robotics updates for guided vehicles

Anthony Casciano President and CEO Siemens Financial Services
Anthony Casciano President and CEO - Siemens Financial Services
0Comments

Siemens has announced advancements in autonomous production by integrating new AI and robotics capabilities into automated guided vehicles. This development is part of the expansion of their Operations Copilot, which now includes AI agents designed for autonomous transport systems.

Additionally, Siemens introduced Safe Velocity software to ensure fail-safe speed monitoring of these autonomous vehicles. These enhancements aim to improve efficiency and safety in industrial environments.

“Expansion of the Operations Copilot with AI agents for autonomous transport systems,” a representative from Siemens stated. The company also emphasized the importance of reliable speed monitoring, noting that “Safe Velocity software enables fail-safe speed monitoring of autonomous vehicles.”

These technological improvements are expected to bolster Siemens’ position in the market for industrial automation solutions.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.